JP2003514818A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003514818A5 JP2003514818A5 JP2001538906A JP2001538906A JP2003514818A5 JP 2003514818 A5 JP2003514818 A5 JP 2003514818A5 JP 2001538906 A JP2001538906 A JP 2001538906A JP 2001538906 A JP2001538906 A JP 2001538906A JP 2003514818 A5 JP2003514818 A5 JP 2003514818A5
- Authority
- JP
- Japan
- Prior art keywords
- oct
- azabicyclo
- propenamide
- phenylpropenamide
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- -1 -CO 2 R 7 Chemical group 0.000 description 26
- 229910052739 hydrogen Inorganic materials 0.000 description 20
- 239000001257 hydrogen Substances 0.000 description 20
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 14
- 125000003118 aryl group Chemical group 0.000 description 13
- 150000001875 compounds Chemical class 0.000 description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 13
- 125000001072 heteroaryl group Chemical group 0.000 description 12
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 9
- 239000008194 pharmaceutical composition Substances 0.000 description 9
- 229910052736 halogen Inorganic materials 0.000 description 8
- 150000002367 halogens Chemical class 0.000 description 8
- 150000003839 salts Chemical class 0.000 description 8
- 229910052717 sulfur Inorganic materials 0.000 description 8
- 125000004430 oxygen atom Chemical group O* 0.000 description 7
- 208000024827 Alzheimer disease Diseases 0.000 description 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 6
- 125000004093 cyano group Chemical group *C#N 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000035475 disorder Diseases 0.000 description 6
- 150000002431 hydrogen Chemical class 0.000 description 6
- 125000004433 nitrogen atom Chemical group N* 0.000 description 6
- 229910052760 oxygen Inorganic materials 0.000 description 6
- 239000001301 oxygen Substances 0.000 description 6
- 125000004434 sulfur atom Chemical group 0.000 description 6
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 description 5
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 description 5
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 4
- 208000000044 Amnesia Diseases 0.000 description 4
- 208000019901 Anxiety disease Diseases 0.000 description 4
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 4
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 4
- 208000020925 Bipolar disease Diseases 0.000 description 4
- 208000019888 Circadian rhythm sleep disease Diseases 0.000 description 4
- 206010009900 Colitis ulcerative Diseases 0.000 description 4
- 208000001456 Jet Lag Syndrome Diseases 0.000 description 4
- 208000009829 Lewy Body Disease Diseases 0.000 description 4
- 201000002832 Lewy body dementia Diseases 0.000 description 4
- 206010026749 Mania Diseases 0.000 description 4
- 208000026139 Memory disease Diseases 0.000 description 4
- 206010057852 Nicotine dependence Diseases 0.000 description 4
- 208000002193 Pain Diseases 0.000 description 4
- 208000018737 Parkinson disease Diseases 0.000 description 4
- 208000025569 Tobacco Use disease Diseases 0.000 description 4
- 208000000323 Tourette Syndrome Diseases 0.000 description 4
- 208000016620 Tourette disease Diseases 0.000 description 4
- 201000006704 Ulcerative Colitis Diseases 0.000 description 4
- 230000036506 anxiety Effects 0.000 description 4
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 description 4
- 208000028683 bipolar I disease Diseases 0.000 description 4
- 230000001713 cholinergic effect Effects 0.000 description 4
- 208000010877 cognitive disease Diseases 0.000 description 4
- 208000033915 jet lag type circadian rhythm sleep disease Diseases 0.000 description 4
- 201000003723 learning disability Diseases 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 230000006984 memory degeneration Effects 0.000 description 4
- 208000023060 memory loss Diseases 0.000 description 4
- 230000004770 neurodegeneration Effects 0.000 description 4
- 208000015122 neurodegenerative disease Diseases 0.000 description 4
- 229960002715 nicotine Drugs 0.000 description 4
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 4
- 201000000980 schizophrenia Diseases 0.000 description 4
- 125000001424 substituent group Chemical group 0.000 description 4
- APEJMQOBVMLION-VOTSOKGWSA-N trans-cinnamamide Chemical compound NC(=O)\C=C\C1=CC=CC=C1 APEJMQOBVMLION-VOTSOKGWSA-N 0.000 description 4
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 description 3
- 0 CC1C(CC2)N(*)C2C1 Chemical compound CC1C(CC2)N(*)C2C1 0.000 description 3
- 208000028698 Cognitive impairment Diseases 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 230000006735 deficit Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
- 210000000225 synapse Anatomy 0.000 description 3
- PHZYWNWABJJERF-AATRIKPKSA-N (e)-3-(2-aminophenyl)-n-(1-azabicyclo[2.2.2]octan-3-yl)prop-2-enamide Chemical compound NC1=CC=CC=C1\C=C\C(=O)NC1C(CC2)CCN2C1 PHZYWNWABJJERF-AATRIKPKSA-N 0.000 description 2
- HSTDTPMOYSFAIB-OWOJBTEDSA-N (e)-n-(1-azabicyclo[2.2.2]octan-3-yl)-3-(1h-imidazol-5-yl)prop-2-enamide Chemical compound C1N(CC2)CCC2C1NC(=O)\C=C\C1=CNC=N1 HSTDTPMOYSFAIB-OWOJBTEDSA-N 0.000 description 2
- DWEFNEVEZVDWPJ-AATRIKPKSA-N (e)-n-(1-azabicyclo[2.2.2]octan-3-yl)-3-(2-fluorophenyl)prop-2-enamide Chemical compound FC1=CC=CC=C1\C=C\C(=O)NC1C(CC2)CCN2C1 DWEFNEVEZVDWPJ-AATRIKPKSA-N 0.000 description 2
- MENCFQRKJSFDJH-AATRIKPKSA-N (e)-n-(1-azabicyclo[2.2.2]octan-3-yl)-3-(2-nitrophenyl)prop-2-enamide Chemical compound [O-][N+](=O)C1=CC=CC=C1\C=C\C(=O)NC1C(CC2)CCN2C1 MENCFQRKJSFDJH-AATRIKPKSA-N 0.000 description 2
- UCRCSZYDUAPEEU-SNAWJCMRSA-N (e)-n-(1-azabicyclo[2.2.2]octan-3-yl)-3-(3-iodophenyl)prop-2-enamide Chemical compound IC1=CC=CC(\C=C\C(=O)NC2C3CCN(CC3)C2)=C1 UCRCSZYDUAPEEU-SNAWJCMRSA-N 0.000 description 2
- GERXVMRTEYKZPQ-QPJJXVBHSA-N (e)-n-(1-azabicyclo[2.2.2]octan-3-yl)-3-(4-methoxyphenyl)prop-2-enamide Chemical compound C1=CC(OC)=CC=C1\C=C\C(=O)NC1C(CC2)CCN2C1 GERXVMRTEYKZPQ-QPJJXVBHSA-N 0.000 description 2
- DXSJNKAJPNKROG-OWOJBTEDSA-N (e)-n-(1-azabicyclo[2.2.2]octan-3-yl)-3-(5-hydroxypyridin-3-yl)prop-2-enamide Chemical compound OC1=CN=CC(\C=C\C(=O)NC2C3CCN(CC3)C2)=C1 DXSJNKAJPNKROG-OWOJBTEDSA-N 0.000 description 2
- NBTHWOKIJJBULB-NSCUHMNNSA-N (e)-n-(1-azabicyclo[2.2.2]octan-3-yl)-3-(5-methoxypyridin-3-yl)prop-2-enamide Chemical compound COC1=CN=CC(\C=C\C(=O)NC2C3CCN(CC3)C2)=C1 NBTHWOKIJJBULB-NSCUHMNNSA-N 0.000 description 2
- MIWLXSRIICDTEX-HNQUOIGGSA-N (e)-n-(1-azabicyclo[2.2.2]octan-3-yl)-3-(5-nitrofuran-2-yl)prop-2-enamide Chemical compound O1C([N+](=O)[O-])=CC=C1\C=C\C(=O)NC1C(CC2)CCN2C1 MIWLXSRIICDTEX-HNQUOIGGSA-N 0.000 description 2
- ATNVHCFFVIVLSM-ONEGZZNKSA-N (e)-n-(1-azabicyclo[2.2.2]octan-3-yl)-3-(furan-2-yl)prop-2-enamide Chemical compound C1N(CC2)CCC2C1NC(=O)\C=C\C1=CC=CO1 ATNVHCFFVIVLSM-ONEGZZNKSA-N 0.000 description 2
- WMUJNOJUYWXQSG-OWOJBTEDSA-N (e)-n-(1-azabicyclo[2.2.2]octan-3-yl)-3-(furan-3-yl)prop-2-enamide Chemical compound C1N(CC2)CCC2C1NC(=O)\C=C\C=1C=COC=1 WMUJNOJUYWXQSG-OWOJBTEDSA-N 0.000 description 2
- QDJIWDUPQLKWAA-SNAWJCMRSA-N (e)-n-(1-azabicyclo[2.2.2]octan-3-yl)-3-[3-(trifluoromethyl)phenyl]prop-2-enamide Chemical compound FC(F)(F)C1=CC=CC(\C=C\C(=O)NC2C3CCN(CC3)C2)=C1 QDJIWDUPQLKWAA-SNAWJCMRSA-N 0.000 description 2
- ODFSOOCVJPIZNA-VOTSOKGWSA-N (e)-n-(1-azabicyclo[2.2.2]octan-3-yl)-3-phenylprop-2-enamide Chemical compound C1N(CC2)CCC2C1NC(=O)\C=C\C1=CC=CC=C1 ODFSOOCVJPIZNA-VOTSOKGWSA-N 0.000 description 2
- NZONTOQHVFUZMV-ONEGZZNKSA-N (e)-n-(1-azabicyclo[2.2.2]octan-3-yl)-3-thiophen-2-ylprop-2-enamide Chemical compound C1N(CC2)CCC2C1NC(=O)\C=C\C1=CC=CS1 NZONTOQHVFUZMV-ONEGZZNKSA-N 0.000 description 2
- NIJKEAAXBOXSNC-OWOJBTEDSA-N (e)-n-(1-azabicyclo[2.2.2]octan-3-yl)-3-thiophen-3-ylprop-2-enamide Chemical compound C1N(CC2)CCC2C1NC(=O)\C=C\C=1C=CSC=1 NIJKEAAXBOXSNC-OWOJBTEDSA-N 0.000 description 2
- QLXOOYGFEACOIW-BQYQJAHWSA-N (e)-n-(1-azabicyclo[2.2.2]octan-3-yl)-n-methyl-3-phenylprop-2-enamide Chemical compound C1N(CC2)CCC2C1N(C)C(=O)\C=C\C1=CC=CC=C1 QLXOOYGFEACOIW-BQYQJAHWSA-N 0.000 description 2
- FKRVCWSLGVBIGB-VOTSOKGWSA-N (e)-n-(3-cyano-1-azabicyclo[2.2.2]octan-3-yl)-3-phenylprop-2-enamide Chemical compound C1N(CC2)CCC2C1(C#N)NC(=O)\C=C\C1=CC=CC=C1 FKRVCWSLGVBIGB-VOTSOKGWSA-N 0.000 description 2
- XZVQIURADIYJDK-BQYQJAHWSA-N (e)-n-(3-methyl-1-azabicyclo[2.2.2]octan-3-yl)-3-phenylprop-2-enamide Chemical compound C1N(CC2)CCC2C1(C)NC(=O)\C=C\C1=CC=CC=C1 XZVQIURADIYJDK-BQYQJAHWSA-N 0.000 description 2
- HSTDTPMOYSFAIB-ISUDXETCSA-N (e)-n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-3-(1h-imidazol-5-yl)prop-2-enamide Chemical compound N([C@@H]1C2CCN(CC2)C1)C(=O)\C=C\C1=CNC=N1 HSTDTPMOYSFAIB-ISUDXETCSA-N 0.000 description 2
- DXSJNKAJPNKROG-YUKKFKLSSA-N (e)-n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-3-(5-hydroxypyridin-3-yl)prop-2-enamide Chemical compound OC1=CN=CC(\C=C\C(=O)N[C@@H]2C3CCN(CC3)C2)=C1 DXSJNKAJPNKROG-YUKKFKLSSA-N 0.000 description 2
- NBTHWOKIJJBULB-FAAWYNLUSA-N (e)-n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-3-(5-methoxypyridin-3-yl)prop-2-enamide Chemical compound COC1=CN=CC(\C=C\C(=O)N[C@@H]2C3CCN(CC3)C2)=C1 NBTHWOKIJJBULB-FAAWYNLUSA-N 0.000 description 2
- MIWLXSRIICDTEX-JWPFQLSCSA-N (e)-n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-3-(5-nitrofuran-2-yl)prop-2-enamide Chemical compound O1C([N+](=O)[O-])=CC=C1\C=C\C(=O)N[C@@H]1C(CC2)CCN2C1 MIWLXSRIICDTEX-JWPFQLSCSA-N 0.000 description 2
- ATNVHCFFVIVLSM-OOPCZODUSA-N (e)-n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-3-(furan-2-yl)prop-2-enamide Chemical compound N([C@@H]1C2CCN(CC2)C1)C(=O)\C=C\C1=CC=CO1 ATNVHCFFVIVLSM-OOPCZODUSA-N 0.000 description 2
- WMUJNOJUYWXQSG-AORQRIRUSA-N (e)-n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-3-(furan-3-yl)prop-2-enamide Chemical compound N([C@@H]1C2CCN(CC2)C1)C(=O)\C=C\C=1C=COC=1 WMUJNOJUYWXQSG-AORQRIRUSA-N 0.000 description 2
- QDJIWDUPQLKWAA-RGDDUWESSA-N (e)-n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-3-[3-(trifluoromethyl)phenyl]prop-2-enamide Chemical compound FC(F)(F)C1=CC=CC(\C=C\C(=O)N[C@@H]2C3CCN(CC3)C2)=C1 QDJIWDUPQLKWAA-RGDDUWESSA-N 0.000 description 2
- NZONTOQHVFUZMV-OOPCZODUSA-N (e)-n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-3-thiophen-2-ylprop-2-enamide Chemical compound N([C@@H]1C2CCN(CC2)C1)C(=O)\C=C\C1=CC=CS1 NZONTOQHVFUZMV-OOPCZODUSA-N 0.000 description 2
- NIJKEAAXBOXSNC-AORQRIRUSA-N (e)-n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-3-thiophen-3-ylprop-2-enamide Chemical compound N([C@@H]1C2CCN(CC2)C1)C(=O)\C=C\C=1C=CSC=1 NIJKEAAXBOXSNC-AORQRIRUSA-N 0.000 description 2
- 201000004311 Gilles de la Tourette syndrome Diseases 0.000 description 2
- 208000023105 Huntington disease Diseases 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000005586 smoking cessation Effects 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- VTOAFAPBGXLGME-SDNWHVSQSA-N (e)-2,3-diphenylprop-2-enamide Chemical compound C=1C=CC=CC=1/C(C(=O)N)=C\C1=CC=CC=C1 VTOAFAPBGXLGME-SDNWHVSQSA-N 0.000 description 1
- PHZYWNWABJJERF-NFAHFFEMSA-N (e)-3-(2-aminophenyl)-n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]prop-2-enamide Chemical compound NC1=CC=CC=C1\C=C\C(=O)N[C@@H]1C(CC2)CCN2C1 PHZYWNWABJJERF-NFAHFFEMSA-N 0.000 description 1
- RCLFFPCOTKNDRK-ZZXKWVIFSA-N (e)-3-(4-aminophenyl)-n-(1-azabicyclo[2.2.2]octan-3-yl)prop-2-enamide Chemical compound C1=CC(N)=CC=C1\C=C\C(=O)NC1C(CC2)CCN2C1 RCLFFPCOTKNDRK-ZZXKWVIFSA-N 0.000 description 1
- LBVMWSPLUKLPOJ-ACCUITESSA-N (e)-n-(1-azabicyclo[2.2.2]octan-3-yl)-2-methyl-3-phenylprop-2-enamide Chemical compound C1N(CC2)CCC2C1NC(=O)C(/C)=C/C1=CC=CC=C1 LBVMWSPLUKLPOJ-ACCUITESSA-N 0.000 description 1
- MFIWCTVYPBIGQT-AATRIKPKSA-N (e)-n-(1-azabicyclo[2.2.2]octan-3-yl)-3-(2-formamidophenyl)prop-2-enamide Chemical compound O=CNC1=CC=CC=C1\C=C\C(=O)NC1C(CC2)CCN2C1 MFIWCTVYPBIGQT-AATRIKPKSA-N 0.000 description 1
- QODFPISBGYJKDV-VOTSOKGWSA-N (e)-n-(1-azabicyclo[2.2.2]octan-3-yl)-3-(2-methoxyphenyl)prop-2-enamide Chemical compound COC1=CC=CC=C1\C=C\C(=O)NC1C(CC2)CCN2C1 QODFPISBGYJKDV-VOTSOKGWSA-N 0.000 description 1
- NVVYTUXHKCMTCD-VOTSOKGWSA-N (e)-n-(1-azabicyclo[2.2.2]octan-3-yl)-3-(2-methylphenyl)prop-2-enamide Chemical compound CC1=CC=CC=C1\C=C\C(=O)NC1C(CC2)CCN2C1 NVVYTUXHKCMTCD-VOTSOKGWSA-N 0.000 description 1
- QOFOUEFCNYRQQX-DUXPYHPUSA-N (e)-n-(1-azabicyclo[2.2.2]octan-3-yl)-3-(3,4-dichlorophenyl)prop-2-enamide Chemical compound C1=C(Cl)C(Cl)=CC=C1\C=C\C(=O)NC1C(CC2)CCN2C1 QOFOUEFCNYRQQX-DUXPYHPUSA-N 0.000 description 1
- TYYMXUGFPLAOSL-SNAWJCMRSA-N (e)-n-(1-azabicyclo[2.2.2]octan-3-yl)-3-(3-bromophenyl)prop-2-enamide Chemical compound BrC1=CC=CC(\C=C\C(=O)NC2C3CCN(CC3)C2)=C1 TYYMXUGFPLAOSL-SNAWJCMRSA-N 0.000 description 1
- OOZULDOHFTVWCS-SNAWJCMRSA-N (e)-n-(1-azabicyclo[2.2.2]octan-3-yl)-3-(3-chlorophenyl)prop-2-enamide Chemical compound ClC1=CC=CC(\C=C\C(=O)NC2C3CCN(CC3)C2)=C1 OOZULDOHFTVWCS-SNAWJCMRSA-N 0.000 description 1
- WHMOYHBOLPOUMR-AATRIKPKSA-N (e)-n-(1-azabicyclo[2.2.2]octan-3-yl)-3-(3-methoxyphenyl)prop-2-enamide Chemical compound COC1=CC=CC(\C=C\C(=O)NC2C3CCN(CC3)C2)=C1 WHMOYHBOLPOUMR-AATRIKPKSA-N 0.000 description 1
- WARWHFWAFGSZMP-ZZXKWVIFSA-N (e)-n-(1-azabicyclo[2.2.2]octan-3-yl)-3-(4-bromophenyl)prop-2-enamide Chemical compound C1=CC(Br)=CC=C1\C=C\C(=O)NC1C(CC2)CCN2C1 WARWHFWAFGSZMP-ZZXKWVIFSA-N 0.000 description 1
- WUSJALGTATXXGB-ZZXKWVIFSA-N (e)-n-(1-azabicyclo[2.2.2]octan-3-yl)-3-(4-chlorophenyl)prop-2-enamide Chemical compound C1=CC(Cl)=CC=C1\C=C\C(=O)NC1C(CC2)CCN2C1 WUSJALGTATXXGB-ZZXKWVIFSA-N 0.000 description 1
- GBLPTBJUUSMWLC-ZZXKWVIFSA-N (e)-n-(1-azabicyclo[2.2.2]octan-3-yl)-3-(4-fluorophenyl)prop-2-enamide Chemical compound C1=CC(F)=CC=C1\C=C\C(=O)NC1C(CC2)CCN2C1 GBLPTBJUUSMWLC-ZZXKWVIFSA-N 0.000 description 1
- VUDAUVWKTXMSDD-ZZXKWVIFSA-N (e)-n-(1-azabicyclo[2.2.2]octan-3-yl)-3-(4-formamidophenyl)prop-2-enamide Chemical compound C1=CC(NC=O)=CC=C1\C=C\C(=O)NC1C(CC2)CCN2C1 VUDAUVWKTXMSDD-ZZXKWVIFSA-N 0.000 description 1
- SYJFKEQPXPZQSF-ZZXKWVIFSA-N (e)-n-(1-azabicyclo[2.2.2]octan-3-yl)-3-(4-iodophenyl)prop-2-enamide Chemical compound C1=CC(I)=CC=C1\C=C\C(=O)NC1C(CC2)CCN2C1 SYJFKEQPXPZQSF-ZZXKWVIFSA-N 0.000 description 1
- LMYLJTJHCPTSPI-ZZXKWVIFSA-N (e)-n-(1-azabicyclo[2.2.2]octan-3-yl)-3-(4-nitrophenyl)prop-2-enamide Chemical compound C1=CC([N+](=O)[O-])=CC=C1\C=C\C(=O)NC1C(CC2)CCN2C1 LMYLJTJHCPTSPI-ZZXKWVIFSA-N 0.000 description 1
- VYJUETVRHRXQFA-AATRIKPKSA-N (e)-n-(1-azabicyclo[2.2.2]octan-3-yl)-3-[2-(trifluoromethyl)phenyl]prop-2-enamide Chemical compound FC(F)(F)C1=CC=CC=C1\C=C\C(=O)NC1C(CC2)CCN2C1 VYJUETVRHRXQFA-AATRIKPKSA-N 0.000 description 1
- HVWIZNLEMLWNOA-ACCUITESSA-N (e)-n-(1-azabicyclo[2.2.2]octan-3-yl)-3-phenylbut-2-enamide Chemical compound C1N(CC2)CCC2C1NC(=O)\C=C(/C)C1=CC=CC=C1 HVWIZNLEMLWNOA-ACCUITESSA-N 0.000 description 1
- QPOFOAHKDBURCL-SNAWJCMRSA-N (e)-n-(1-azabicyclo[2.2.2]octan-3-yl)-3-pyridin-2-ylprop-2-enamide Chemical compound C1N(CC2)CCC2C1NC(=O)\C=C\C1=CC=CC=N1 QPOFOAHKDBURCL-SNAWJCMRSA-N 0.000 description 1
- IFRBWXFNEPBBKA-ONEGZZNKSA-N (e)-n-(1-azabicyclo[2.2.2]octan-3-yl)-3-pyridin-3-ylprop-2-enamide Chemical compound C1N(CC2)CCC2C1NC(=O)\C=C\C1=CC=CN=C1 IFRBWXFNEPBBKA-ONEGZZNKSA-N 0.000 description 1
- XELSBDUTKCSMDH-OWOJBTEDSA-N (e)-n-(1-azabicyclo[2.2.2]octan-3-yl)-3-pyridin-4-ylprop-2-enamide Chemical compound C1N(CC2)CCC2C1NC(=O)\C=C\C1=CC=NC=C1 XELSBDUTKCSMDH-OWOJBTEDSA-N 0.000 description 1
- FJJBZFQDEHWYCR-MEPUESOJSA-N (e)-n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-2,3-diphenylprop-2-enamide Chemical compound N([C@@H]1C2CCN(CC2)C1)C(=O)C(\C=1C=CC=CC=1)=C\C1=CC=CC=C1 FJJBZFQDEHWYCR-MEPUESOJSA-N 0.000 description 1
- LBVMWSPLUKLPOJ-BYIUCRAPSA-N (e)-n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-2-methyl-3-phenylprop-2-enamide Chemical compound N([C@@H]1C2CCN(CC2)C1)C(=O)C(/C)=C/C1=CC=CC=C1 LBVMWSPLUKLPOJ-BYIUCRAPSA-N 0.000 description 1
- MFIWCTVYPBIGQT-JFDDCEBESA-N (e)-n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-3-(2-formamidophenyl)prop-2-enamide Chemical compound O=CNC1=CC=CC=C1\C=C\C(=O)N[C@@H]1C(CC2)CCN2C1 MFIWCTVYPBIGQT-JFDDCEBESA-N 0.000 description 1
- NVVYTUXHKCMTCD-MOEXGYKKSA-N (e)-n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-3-(2-methylphenyl)prop-2-enamide Chemical compound CC1=CC=CC=C1\C=C\C(=O)N[C@@H]1C(CC2)CCN2C1 NVVYTUXHKCMTCD-MOEXGYKKSA-N 0.000 description 1
- MENCFQRKJSFDJH-GJBLVYBDSA-N (e)-n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-3-(2-nitrophenyl)prop-2-enamide Chemical compound [O-][N+](=O)C1=CC=CC=C1\C=C\C(=O)N[C@@H]1C(CC2)CCN2C1 MENCFQRKJSFDJH-GJBLVYBDSA-N 0.000 description 1
- QOFOUEFCNYRQQX-OMDKTOEGSA-N (e)-n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-3-(3,4-dichlorophenyl)prop-2-enamide Chemical compound C1=C(Cl)C(Cl)=CC=C1\C=C\C(=O)N[C@@H]1C(CC2)CCN2C1 QOFOUEFCNYRQQX-OMDKTOEGSA-N 0.000 description 1
- TYYMXUGFPLAOSL-RGDDUWESSA-N (e)-n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-3-(3-bromophenyl)prop-2-enamide Chemical compound BrC1=CC=CC(\C=C\C(=O)N[C@@H]2C3CCN(CC3)C2)=C1 TYYMXUGFPLAOSL-RGDDUWESSA-N 0.000 description 1
- OOZULDOHFTVWCS-RGDDUWESSA-N (e)-n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-3-(3-chlorophenyl)prop-2-enamide Chemical compound ClC1=CC=CC(\C=C\C(=O)N[C@@H]2C3CCN(CC3)C2)=C1 OOZULDOHFTVWCS-RGDDUWESSA-N 0.000 description 1
- YAUMYTQGLWXDIH-RGDDUWESSA-N (e)-n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-3-(3-fluorophenyl)prop-2-enamide Chemical compound FC1=CC=CC(\C=C\C(=O)N[C@@H]2C3CCN(CC3)C2)=C1 YAUMYTQGLWXDIH-RGDDUWESSA-N 0.000 description 1
- WHMOYHBOLPOUMR-JFDDCEBESA-N (e)-n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-3-(3-methoxyphenyl)prop-2-enamide Chemical compound COC1=CC=CC(\C=C\C(=O)N[C@@H]2C3CCN(CC3)C2)=C1 WHMOYHBOLPOUMR-JFDDCEBESA-N 0.000 description 1
- WARWHFWAFGSZMP-VFQAQYNWSA-N (e)-n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-3-(4-bromophenyl)prop-2-enamide Chemical compound C1=CC(Br)=CC=C1\C=C\C(=O)N[C@@H]1C(CC2)CCN2C1 WARWHFWAFGSZMP-VFQAQYNWSA-N 0.000 description 1
- WUSJALGTATXXGB-VFQAQYNWSA-N (e)-n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-3-(4-chlorophenyl)prop-2-enamide Chemical compound C1=CC(Cl)=CC=C1\C=C\C(=O)N[C@@H]1C(CC2)CCN2C1 WUSJALGTATXXGB-VFQAQYNWSA-N 0.000 description 1
- GBLPTBJUUSMWLC-VFQAQYNWSA-N (e)-n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-3-(4-fluorophenyl)prop-2-enamide Chemical compound C1=CC(F)=CC=C1\C=C\C(=O)N[C@@H]1C(CC2)CCN2C1 GBLPTBJUUSMWLC-VFQAQYNWSA-N 0.000 description 1
- VUDAUVWKTXMSDD-GIZXNFQBSA-N (e)-n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-3-(4-formamidophenyl)prop-2-enamide Chemical compound C1=CC(NC=O)=CC=C1\C=C\C(=O)N[C@@H]1C(CC2)CCN2C1 VUDAUVWKTXMSDD-GIZXNFQBSA-N 0.000 description 1
- GERXVMRTEYKZPQ-RRGWEWPQSA-N (e)-n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-3-(4-methoxyphenyl)prop-2-enamide Chemical compound C1=CC(OC)=CC=C1\C=C\C(=O)N[C@@H]1C(CC2)CCN2C1 GERXVMRTEYKZPQ-RRGWEWPQSA-N 0.000 description 1
- LMYLJTJHCPTSPI-VFQAQYNWSA-N (e)-n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-3-(4-nitrophenyl)prop-2-enamide Chemical compound C1=CC([N+](=O)[O-])=CC=C1\C=C\C(=O)N[C@@H]1C(CC2)CCN2C1 LMYLJTJHCPTSPI-VFQAQYNWSA-N 0.000 description 1
- HVWIZNLEMLWNOA-BYIUCRAPSA-N (e)-n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-3-phenylbut-2-enamide Chemical compound N([C@@H]1C2CCN(CC2)C1)C(=O)\C=C(/C)C1=CC=CC=C1 HVWIZNLEMLWNOA-BYIUCRAPSA-N 0.000 description 1
- ODFSOOCVJPIZNA-LFAOLKIESA-N (e)-n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-3-phenylprop-2-enamide Chemical compound N([C@@H]1C2CCN(CC2)C1)C(=O)\C=C\C1=CC=CC=C1 ODFSOOCVJPIZNA-LFAOLKIESA-N 0.000 description 1
- QPOFOAHKDBURCL-NNTXTVRGSA-N (e)-n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-3-pyridin-2-ylprop-2-enamide Chemical compound N([C@@H]1C2CCN(CC2)C1)C(=O)\C=C\C1=CC=CC=N1 QPOFOAHKDBURCL-NNTXTVRGSA-N 0.000 description 1
- IFRBWXFNEPBBKA-XGACYXMMSA-N (e)-n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-3-pyridin-3-ylprop-2-enamide Chemical compound N([C@@H]1C2CCN(CC2)C1)C(=O)\C=C\C1=CC=CN=C1 IFRBWXFNEPBBKA-XGACYXMMSA-N 0.000 description 1
- XELSBDUTKCSMDH-YUKKFKLSSA-N (e)-n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-3-pyridin-4-ylprop-2-enamide Chemical compound N([C@@H]1C2CCN(CC2)C1)C(=O)\C=C\C1=CC=NC=C1 XELSBDUTKCSMDH-YUKKFKLSSA-N 0.000 description 1
- LBVMWSPLUKLPOJ-SICOMBFOSA-N (e)-n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-2-methyl-3-phenylprop-2-enamide Chemical compound N([C@H]1C2CCN(CC2)C1)C(=O)C(/C)=C/C1=CC=CC=C1 LBVMWSPLUKLPOJ-SICOMBFOSA-N 0.000 description 1
- NVVYTUXHKCMTCD-FYCOFBDGSA-N (e)-n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-3-(2-methylphenyl)prop-2-enamide Chemical compound CC1=CC=CC=C1\C=C\C(=O)N[C@H]1C(CC2)CCN2C1 NVVYTUXHKCMTCD-FYCOFBDGSA-N 0.000 description 1
- MENCFQRKJSFDJH-VBROQKIQSA-N (e)-n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-3-(2-nitrophenyl)prop-2-enamide Chemical compound [O-][N+](=O)C1=CC=CC=C1\C=C\C(=O)N[C@H]1C(CC2)CCN2C1 MENCFQRKJSFDJH-VBROQKIQSA-N 0.000 description 1
- ODFSOOCVJPIZNA-LQYUOIDQSA-N (e)-n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-3-phenylprop-2-enamide Chemical compound N([C@H]1C2CCN(CC2)C1)C(=O)\C=C\C1=CC=CC=C1 ODFSOOCVJPIZNA-LQYUOIDQSA-N 0.000 description 1
- MGQYIEIAFOISHD-UVTDQMKNSA-N (z)-n-(1-azabicyclo[2.2.2]octan-3-yl)-2-fluoro-3-phenylprop-2-enamide Chemical compound C1N(CC2)CCC2C1NC(=O)C(/F)=C/C1=CC=CC=C1 MGQYIEIAFOISHD-UVTDQMKNSA-N 0.000 description 1
- QODFPISBGYJKDV-SREVYHEPSA-N (z)-n-(1-azabicyclo[2.2.2]octan-3-yl)-3-(2-methoxyphenyl)prop-2-enamide Chemical compound COC1=CC=CC=C1\C=C/C(=O)NC1C(CC2)CCN2C1 QODFPISBGYJKDV-SREVYHEPSA-N 0.000 description 1
- HVWIZNLEMLWNOA-QBFSEMIESA-N (z)-n-(1-azabicyclo[2.2.2]octan-3-yl)-3-phenylbut-2-enamide Chemical compound C1N(CC2)CCC2C1NC(=O)/C=C(/C)C1=CC=CC=C1 HVWIZNLEMLWNOA-QBFSEMIESA-N 0.000 description 1
- ODFSOOCVJPIZNA-SREVYHEPSA-N (z)-n-(1-azabicyclo[2.2.2]octan-3-yl)-3-phenylprop-2-enamide Chemical compound C1N(CC2)CCC2C1NC(=O)\C=C/C1=CC=CC=C1 ODFSOOCVJPIZNA-SREVYHEPSA-N 0.000 description 1
- MGQYIEIAFOISHD-LTBFUDJGSA-N (z)-n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-2-fluoro-3-phenylprop-2-enamide Chemical compound N([C@@H]1C2CCN(CC2)C1)C(=O)C(/F)=C/C1=CC=CC=C1 MGQYIEIAFOISHD-LTBFUDJGSA-N 0.000 description 1
- QODFPISBGYJKDV-XHPSBEMXSA-N (z)-n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-3-(2-methoxyphenyl)prop-2-enamide Chemical compound COC1=CC=CC=C1\C=C/C(=O)N[C@@H]1C(CC2)CCN2C1 QODFPISBGYJKDV-XHPSBEMXSA-N 0.000 description 1
- HVWIZNLEMLWNOA-KVNDZABWSA-N (z)-n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-3-phenylbut-2-enamide Chemical compound N([C@@H]1C2CCN(CC2)C1)C(=O)/C=C(/C)C1=CC=CC=C1 HVWIZNLEMLWNOA-KVNDZABWSA-N 0.000 description 1
- ODFSOOCVJPIZNA-XHPSBEMXSA-N (z)-n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-3-phenylprop-2-enamide Chemical compound N([C@@H]1C2CCN(CC2)C1)C(=O)\C=C/C1=CC=CC=C1 ODFSOOCVJPIZNA-XHPSBEMXSA-N 0.000 description 1
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 125000006306 4-iodophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1I 0.000 description 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 201000006347 Intellectual Disability Diseases 0.000 description 1
- 208000020358 Learning disease Diseases 0.000 description 1
- 102000019315 Nicotinic acetylcholine receptors Human genes 0.000 description 1
- 108050006807 Nicotinic acetylcholine receptors Proteins 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 102000047725 alpha7 Nicotinic Acetylcholine Receptor Human genes 0.000 description 1
- 108700006085 alpha7 Nicotinic Acetylcholine Receptor Proteins 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- BVFZXSDFGCHDCH-UHFFFAOYSA-N n-(1-azabicyclo[2.2.2]octan-3-yl)-3-phenylprop-2-ynamide Chemical compound C1N(CC2)CCC2C1NC(=O)C#CC1=CC=CC=C1 BVFZXSDFGCHDCH-UHFFFAOYSA-N 0.000 description 1
- BVFZXSDFGCHDCH-HNNXBMFYSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-3-phenylprop-2-ynamide Chemical compound N([C@@H]1C2CCN(CC2)C1)C(=O)C#CC1=CC=CC=C1 BVFZXSDFGCHDCH-HNNXBMFYSA-N 0.000 description 1
- BVFZXSDFGCHDCH-OAHLLOKOSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-3-phenylprop-2-ynamide Chemical compound N([C@H]1C2CCN(CC2)C1)C(=O)C#CC1=CC=CC=C1 BVFZXSDFGCHDCH-OAHLLOKOSA-N 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000000946 synaptic effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9904176-6 | 1999-11-18 | ||
| SE9904176A SE9904176D0 (sv) | 1999-11-18 | 1999-11-18 | New use |
| PCT/SE2000/002262 WO2001036417A1 (en) | 1999-11-18 | 2000-11-16 | New use and novel n-azabicyclo-amide derivatives |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003514818A JP2003514818A (ja) | 2003-04-22 |
| JP2003514818A5 true JP2003514818A5 (https=) | 2007-11-15 |
Family
ID=20417766
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001538906A Pending JP2003514818A (ja) | 1999-11-18 | 2000-11-16 | 新規使用および新規ｎ−アザビシクロ−アミド誘導体 |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US6683090B1 (https=) |
| EP (1) | EP1233964B1 (https=) |
| JP (1) | JP2003514818A (https=) |
| KR (1) | KR20020058014A (https=) |
| CN (1) | CN1217943C (https=) |
| AR (1) | AR031680A1 (https=) |
| AT (1) | ATE298337T1 (https=) |
| AU (1) | AU784400B2 (https=) |
| BG (1) | BG106680A (https=) |
| BR (1) | BR0015624A (https=) |
| CA (1) | CA2389604A1 (https=) |
| CO (1) | CO5261607A1 (https=) |
| CZ (1) | CZ20021692A3 (https=) |
| DE (1) | DE60020994T2 (https=) |
| DK (1) | DK1233964T3 (https=) |
| EE (1) | EE200200251A (https=) |
| ES (1) | ES2242653T3 (https=) |
| HU (1) | HUP0204245A3 (https=) |
| IL (1) | IL149374A0 (https=) |
| IS (1) | IS6385A (https=) |
| MX (1) | MXPA02004911A (https=) |
| NO (1) | NO20022289L (https=) |
| NZ (1) | NZ518571A (https=) |
| PL (1) | PL355867A1 (https=) |
| PT (1) | PT1233964E (https=) |
| SE (1) | SE9904176D0 (https=) |
| SK (1) | SK6772002A3 (https=) |
| UA (1) | UA74172C2 (https=) |
| WO (1) | WO2001036417A1 (https=) |
| ZA (1) | ZA200203316B (https=) |
Families Citing this family (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7214686B2 (en) | 1997-06-30 | 2007-05-08 | Targacept, Inc. | Pharmaceutical compositions and methods for effecting dopamine release |
| SE0000540D0 (sv) | 2000-02-18 | 2000-02-18 | Astrazeneca Ab | New compounds |
| US6492385B2 (en) | 2000-08-18 | 2002-12-10 | Pharmacia & Upjohn Company | Quinuclidine-substituted heteroaryl moieties for treatment of disease |
| US6486172B2 (en) | 2000-08-18 | 2002-11-26 | Pharmacia & Upjohn Company | Quinuclidine-substituted aryl compounds for treatment of disease |
| US6479510B2 (en) | 2000-08-18 | 2002-11-12 | Pharmacia & Upjohn Company | Quinuclidine-substituted aryl compounds for treatment of disease |
| US6492386B2 (en) * | 2000-08-18 | 2002-12-10 | Pharmacia & Upjohn Company | Quinuclidine-substituted aryl compounds for treatment of disease |
| WO2002017358A2 (en) * | 2000-08-21 | 2002-02-28 | Pharmacia & Upjohn Company | Quinuclidine-substituted heteroaryl moieties for treatment of disease (nicotinic acetylcholine receptor antagonists) |
| US6599916B2 (en) | 2000-08-21 | 2003-07-29 | Pharmacia & Upjohn Company | Quinuclidine-substituted heteroaryl moieties for treatment of disease |
| EP1311505A2 (en) * | 2000-08-21 | 2003-05-21 | PHARMACIA & UPJOHN COMPANY | Quinuclidine-substituted heteroaryl moieties for treatment of disease ( nicotinic acetylcholine receptor ligands ) |
| PE20021019A1 (es) | 2001-04-19 | 2002-11-13 | Upjohn Co | Grupos azabiciclicos sustituidos |
| AR036040A1 (es) | 2001-06-12 | 2004-08-04 | Upjohn Co | Compuestos de heteroarilo multiciclicos sustituidos con quinuclidinas y composiciones farmaceuticas que los contienen |
| AR036041A1 (es) | 2001-06-12 | 2004-08-04 | Upjohn Co | Compuestos aromaticos heterociclicos sustituidos con quinuclidina y composiciones farmaceuticas que los contienen |
| MXPA04000012A (es) * | 2001-07-06 | 2004-05-21 | Neurosearch As | Compuestos novedosos, su preparacion y uso. |
| BR0212101A (pt) | 2001-08-24 | 2004-08-24 | Pharmacia & Up John Company | 7-aza [2.2.1] biciclo-heptanos substituìdos com heteroarila para o tratamento de doenças |
| HUP0402289A2 (hu) * | 2001-10-02 | 2005-02-28 | Pharmacia & Upjohn Company | Gyógyhatású azabiciklusos csoporttal helyettesített kondenzált heteroaril-származékok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk |
| AU2002339810A1 (en) * | 2001-10-16 | 2003-04-28 | Astrazeneca Ab | Azabicyclic compounds for the treatment of fibromyalgia syndrome |
| BR0213760A (pt) * | 2001-10-26 | 2004-10-19 | Upjohn Co | Composto, composição farmacêutica, uso do composto e método para tratamento de doença ou condição |
| US6849620B2 (en) | 2001-10-26 | 2005-02-01 | Pfizer Inc | N-(azabicyclo moieties)-substituted hetero-bicyclic aromatic compounds for the treatment of disease |
| US6919359B2 (en) | 2001-11-08 | 2005-07-19 | Pfizer Inc | Azabicyclic-substituted-heteroaryl compounds for the treatment of disease |
| US6951868B2 (en) | 2001-11-09 | 2005-10-04 | Pfizer Inc. | Azabicyclic-phenyl-fused-heterocyclic compounds for treatment of disease |
| EP1463481A4 (en) | 2001-12-14 | 2008-06-25 | Targacept Inc | METHOD AND COMPOSITIONS FOR TREATING DISORDERS OF THE CENTRAL NERVOUS SYSTEM |
| DE10164139A1 (de) | 2001-12-27 | 2003-07-10 | Bayer Ag | 2-Heteroarylcarbonsäureamide |
| US6852716B2 (en) | 2002-02-15 | 2005-02-08 | Pfizer Inc | Substituted-aryl compounds for treatment of disease |
| AU2003217275A1 (en) | 2002-02-19 | 2003-09-09 | Pharmacia And Upjohn Company | Azabicyclic compounds for the treatment of disease |
| JP2005523288A (ja) | 2002-02-19 | 2005-08-04 | ファルマシア・アンド・アップジョン・カンパニー・エルエルシー | 疾病治療用の縮合した二環式−ｎ−架橋−複素環式芳香族カルボキサミド |
| AU2003227522A1 (en) | 2002-05-30 | 2003-12-19 | Neurosearch A/S | 3-substituted quinuclidines and their use |
| EP1542999A1 (en) | 2002-08-01 | 2005-06-22 | Pharmacia & Upjohn Company LLC | 1h-pyrazole and 1h-pyrrole-azabicyclic compounds with alfa-7 nachr activity |
| JP2006501246A (ja) | 2002-08-30 | 2006-01-12 | メモリー・ファーマシューティカルズ・コーポレイション | 神経変性疾患の治療において有用なアナバセイン誘導体 |
| GB0220581D0 (en) | 2002-09-04 | 2002-10-09 | Novartis Ag | Organic Compound |
| MXPA05003317A (es) | 2002-09-25 | 2005-07-05 | Memory Pharm Corp | Indazoles, benzotiazoles y benzoisotiazoles asi como preparacion y usos de los mismos. |
| KR20050085535A (ko) * | 2002-12-11 | 2005-08-29 | 파마시아 앤드 업존 캄파니 엘엘씨 | 알파 7 니코틴성 아세틸콜린 수용체 아고니스트와 다른화합물의 조합물을 사용한 질환의 치료 방법 |
| AU2004282201A1 (en) | 2003-10-15 | 2005-04-28 | Targacept, Inc. | Azabicycyclic compounds for relieving pain and treating central nervous system disorders |
| NZ550534A (en) | 2004-03-25 | 2009-07-31 | Memory Pharm Corp | Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, and preparation and uses thereof |
| PE20060437A1 (es) | 2004-06-18 | 2006-06-08 | Novartis Ag | COMPUESTOS AZA-BICICLONONANOS COMO LIGANDOS COLINERGICOS DE nAChR |
| GB0415746D0 (en) | 2004-07-14 | 2004-08-18 | Novartis Ag | Organic compounds |
| BRPI0614874A2 (pt) | 2005-08-22 | 2011-04-19 | Targacept Inc | diazatricicloalcanos substituìdos com heteroarila, métodos para sua preparação e uso dos mesmos |
| WO2007037258A1 (ja) * | 2005-09-28 | 2007-04-05 | Kumamoto University | 注意欠陥・多動性障害の治療薬 |
| GB0521508D0 (en) | 2005-10-21 | 2005-11-30 | Novartis Ag | Organic compounds |
| GB0525673D0 (en) | 2005-12-16 | 2006-01-25 | Novartis Ag | Organic compounds |
| GB0525672D0 (en) | 2005-12-16 | 2006-01-25 | Novartis Ag | Organic compounds |
| WO2008008884A2 (en) * | 2006-07-12 | 2008-01-17 | Cornell Research Foundation, Inc. | Inhibition of beta-amyloid peptide aggregation |
| TW200901974A (en) | 2007-01-16 | 2009-01-16 | Wyeth Corp | Compounds, compositions, and methods of making and using them |
| SA08290475B1 (ar) | 2007-08-02 | 2013-06-22 | Targacept Inc | (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه |
| DK2217597T3 (da) | 2007-10-01 | 2011-06-20 | Comentis Inc | Quinuclidin-4-ylmethyl-1h-indol-3-carboxylatderivater som alpha-7-nicotin-acetylcholin-receptor-ligander til behandling af Alzheimers sygdom |
| JP2011511845A (ja) | 2008-02-13 | 2011-04-14 | ターガセプト，インコーポレイテッド | アルファ７（α７）ニコチン作動薬と抗精神病薬との組合せ物 |
| TW201031664A (en) | 2009-01-26 | 2010-09-01 | Targacept Inc | Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide |
| AR081402A1 (es) | 2010-05-17 | 2012-08-29 | Envivo Pharmaceuticals Inc | Una forma cristalina de clorhidrato de (r)-7-cloro-n-(quinuclidin-3-il) benzo(b)tiofeno-2-carboxamida monohidrato |
| FR2974365B1 (fr) * | 2011-04-20 | 2017-08-25 | Centre Nat De La Rech Scient (C N R S) | 1,2,3-triazoles 1,4-disubstituees, leurs procedes de preparation et leurs utilisations diagnostiques et therapeutiques |
| WO2012177856A2 (en) * | 2011-06-21 | 2012-12-27 | Adispell, Inc. | Cognition modification |
| GB201111705D0 (en) | 2011-07-07 | 2011-08-24 | Takeda Pharmaceutical | Compounds and their use |
| GB201111704D0 (en) | 2011-07-07 | 2011-08-24 | Takeda Pharmaceutical | Novel compounds |
| JO3115B1 (ar) | 2011-08-22 | 2017-09-20 | Takeda Pharmaceuticals Co | مركبات بيريدازينون واستخدامها كمثبطات daao |
| CA2872005A1 (en) | 2012-05-08 | 2013-11-14 | Forum Pharmaceuticals, Inc. | Methods of maintaining, treating or improving cognitive function |
| GB201209587D0 (en) | 2012-05-30 | 2012-07-11 | Takeda Pharmaceutical | Therapeutic compounds |
| WO2014122474A1 (en) | 2013-02-07 | 2014-08-14 | Takeda Pharmaceutical Company Limited | Piperidin-1 -yl and azepin-1 -yl carboxylates as muscarinic m4 receptor agonists |
| HK1219722A1 (zh) | 2013-06-21 | 2017-04-13 | Takeda Pharmaceutical Company Limited | 1-磺酰基派啶衍生物作为前动力蛋白受体的调节剂 |
| GB201314286D0 (en) | 2013-08-08 | 2013-09-25 | Takeda Pharmaceutical | Therapeutic Compounds |
| GB201318222D0 (en) | 2013-10-15 | 2013-11-27 | Takeda Pharmaceutical | Novel compounds |
| GB201320905D0 (en) | 2013-11-27 | 2014-01-08 | Takeda Pharmaceutical | Therapeutic compounds |
| TW201613864A (en) | 2014-02-20 | 2016-04-16 | Takeda Pharmaceutical | Novel compounds |
| US20170166561A1 (en) | 2014-07-11 | 2017-06-15 | Alpharmagen, Llc | Quinuclidine compounds for modulating alpha7-nicotinic acetylcholine receptor activity |
| US9724340B2 (en) | 2015-07-31 | 2017-08-08 | Attenua, Inc. | Antitussive compositions and methods |
| GB201616839D0 (en) | 2016-10-04 | 2016-11-16 | Takeda Pharmaceutical Company Limited | Therapeutic compounds |
| GB201619514D0 (en) | 2016-11-18 | 2017-01-04 | Takeda Pharmaceuticals Co | Novel compounds |
| JP2021138648A (ja) | 2020-03-04 | 2021-09-16 | 武田薬品工業株式会社 | 経口固形製剤 |
| GB202414197D0 (en) | 2024-09-27 | 2024-11-13 | Addex Pharmaceuticals Sa | Novel compounds |
| GB202414193D0 (en) | 2024-09-27 | 2024-11-13 | Addex Pharmaceuticals Sa | Novel compounds |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1255467B (it) | 1992-07-29 | 1995-11-02 | Dompe Farmaceutici Spa | Ammidi acriliche farmacologicamente attive |
| GB9304500D0 (en) | 1993-03-05 | 1993-04-21 | Glaxo Spa | Heterocyclic compounds |
| US5981525A (en) * | 1995-01-10 | 1999-11-09 | Smithkline Beecham Corporation | Indole derivatives useful in the treatment of osteoporosis |
-
1999
- 1999-11-18 SE SE9904176A patent/SE9904176D0/xx unknown
-
2000
- 2000-11-06 AR ARP000105840A patent/AR031680A1/es not_active Application Discontinuation
- 2000-11-16 PT PT00981994T patent/PT1233964E/pt unknown
- 2000-11-16 EP EP00981994A patent/EP1233964B1/en not_active Expired - Lifetime
- 2000-11-16 KR KR1020027006257A patent/KR20020058014A/ko not_active Ceased
- 2000-11-16 CZ CZ20021692A patent/CZ20021692A3/cs unknown
- 2000-11-16 US US10/130,635 patent/US6683090B1/en not_active Expired - Fee Related
- 2000-11-16 AU AU19073/01A patent/AU784400B2/en not_active Ceased
- 2000-11-16 IL IL14937400A patent/IL149374A0/xx unknown
- 2000-11-16 SK SK677-2002A patent/SK6772002A3/sk unknown
- 2000-11-16 WO PCT/SE2000/002262 patent/WO2001036417A1/en not_active Ceased
- 2000-11-16 ES ES00981994T patent/ES2242653T3/es not_active Expired - Lifetime
- 2000-11-16 NZ NZ518571A patent/NZ518571A/en unknown
- 2000-11-16 CN CN008184216A patent/CN1217943C/zh not_active Expired - Fee Related
- 2000-11-16 DK DK00981994T patent/DK1233964T3/da active
- 2000-11-16 MX MXPA02004911A patent/MXPA02004911A/es active IP Right Grant
- 2000-11-16 AT AT00981994T patent/ATE298337T1/de not_active IP Right Cessation
- 2000-11-16 HU HU0204245A patent/HUP0204245A3/hu unknown
- 2000-11-16 UA UA2002065003A patent/UA74172C2/uk unknown
- 2000-11-16 EE EEP200200251A patent/EE200200251A/xx unknown
- 2000-11-16 BR BR0015624-8A patent/BR0015624A/pt not_active IP Right Cessation
- 2000-11-16 CA CA002389604A patent/CA2389604A1/en not_active Abandoned
- 2000-11-16 DE DE60020994T patent/DE60020994T2/de not_active Expired - Fee Related
- 2000-11-16 JP JP2001538906A patent/JP2003514818A/ja active Pending
- 2000-11-16 PL PL00355867A patent/PL355867A1/xx not_active Application Discontinuation
- 2000-11-17 CO CO00087729A patent/CO5261607A1/es not_active Application Discontinuation
-
2002
- 2002-04-25 ZA ZA200203316A patent/ZA200203316B/xx unknown
- 2002-05-09 BG BG106680A patent/BG106680A/bg unknown
- 2002-05-14 NO NO20022289A patent/NO20022289L/no unknown
- 2002-05-15 IS IS6385A patent/IS6385A/is unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2003514818A5 (https=) | ||
| RU2002118302A (ru) | Новые биарилкарбоксамиды | |
| JP2003512374A5 (https=) | ||
| JP2006507241A5 (https=) | ||
| JP2003513073A5 (https=) | ||
| JP2005527588A5 (https=) | ||
| ES2242653T3 (es) | Nuevo uso y nuevos derivados de n-azabiciclo-amida. | |
| RU2001122812A (ru) | Новые аралкиламины спирофуропиридинов, полезные в терапии | |
| JP2007532637A5 (https=) | ||
| JP2001510194A5 (https=) | ||
| US6500840B2 (en) | Quinuclidine-substituted heteroaryl moieties for treatment of disease | |
| JP2005539030A5 (https=) | ||
| JP2003513071A5 (https=) | ||
| JP2004532877A5 (https=) | ||
| RU99128075A (ru) | Производные 8-азабицикло(3,2,1)окт-2-ена и-октана в качестве холинергических лигандов на ацх-рецепторах | |
| US7674794B2 (en) | Fused bicycloheterocycle substituted quinuclidine derivatives | |
| JP2005504058A5 (https=) | ||
| JP2005534624A5 (https=) | ||
| RU2009126341A (ru) | НОВЫЕ ПРОИЗВОДНЫЕ 2-(1-АЗА-БИЦИКЛО[2.2.2.]ОКТ-3-ИЛ)-2,3-ДИГИДРОИЗОИНДОЛ-1-ОНА/5,6-ДИГИДРО-ФУРО[2,3-c]ПИРРОЛ-4-ОНА В КАЧЕСТВЕ ЛИГАНДОВ К АЛЬФА 7 НИКОТИНОВОМУ АЦЕТИЛХОЛИНОВОМУ РЕЦЕПТОРУ | |
| ZA200502465B (en) | Indazoles, benzothiazoles, and benzoisothiazoles, and preparation and uses thereof | |
| JP2007515486A (ja) | ３−キヌクリジニルヘテロ原子架橋ビアリール誘導体 | |
| ATE524455T1 (de) | Therapeutische mittel zur schmerzbehandlung | |
| JP2007515479A5 (https=) | ||
| RU2006125636A (ru) | Лиганды никотиновых рецепторов ацетилхолина | |
| JP2008508365A5 (https=) |